Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
| ▸ | PEPD | P12955 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.34 |
| ▸ | SCN4A | P35499 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18084469 | 1.00 | NR1H2 (0.42) | NR1H2NR1H3PEPDPTPN1HSD17B10 | |
| SCHEMBL12773345 | 0.87 | PEPD (0.49) | NR1H2NR1H3PEPDPTPN1HSD17B10 | |
| SCHEMBL27274306 | 0.87 | PEPD (0.49) | NR1H2NR1H3PEPDPTPN1HSD17B10 | |
| SCHEMBL13859052 | 0.87 | PEPD (0.49) | NR1H2NR1H3PEPDPTPN1HSD17B10 | |
| SCHEMBL8255174 | 0.86 | NR1H2 (0.42) | NR1H2NR1H3PTPN1HSD17B10IMPDH2 | |
| SCHEMBL24915083 | 0.85 | PEPD (0.34) | NR1H2NR1H3PEPDPTPN1HSD17B10 | |
| SCHEMBL14488388 | 0.85 | HSD17B10 (0.46) | NR1H2NR1H3HSD17B10EPHX2SMN1; SMN2 | |
| SCHEMBL16824583 | 0.85 | HSD17B10 (0.46) | NR1H2NR1H3HSD17B10EPHX2SMN1; SMN2 | |
| SCHEMBL19389900 | 0.85 | HSD17B10 (0.40) | HSD17B10EPHX2SMN1; SMN2NPC1LMNA | |
| SCHEMBL934024 | 0.85 | HSD17B10 (0.46) | NR1H2NR1H3HSD17B10EPHX2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12544365-B2 | Pharmaceutical combination of an EP4 antagonist and immune checkpoint inhibitors for the treatment of tumours | ROTTAPHARM BIOTECH S.R.L. (IT) | 2026-02-10 | — | — | US | disclosed |
| EP-4065113-B1 | (R)-4-(1-(6-(4-(TRIFLUOROMETHYL)BENZYL)-6-AZASPIRO[2.5]OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL) BENZOIC ACID OR ITS SALT ALSO IN POLYMORPHIC FORM A FOR USE IN THE PREVENTION OF HETEROTOPIC OSSIFICATION | Rottapharm Biotech Srl (IT) | 2024-01-10 | — | — | EP | disclosed |
| US-11590114-B2 | Pharmaceutical combination of an EP4 antagonist and immune checkpoint inhibitors for the treatment of tumours | ROTTAPHARM BIOTECH S.R.L. (IT) | 2023-02-28 | — | — | US | disclosed |
| US-20230028519-A1 | (R)-4-(1-(6-(4-(TRIFLUOROMETHYL)BENZYL)-6-AZASPIRO[2.5] OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL) BENZOIC ACID OR ITS SALT ALSO IN POLYMORPHIC FORM A FOR USE IN THE PREVENTION OF HETEROTOPIC OSSIFICATION | ROTTAPHARM BIOTECH S.R.L. (IT) | 2023-01-26 | — | — | US | disclosed |
| CN-115515936-A | Process for the preparation of (R) -4- (1- (6- (4- (trifluoromethyl) benzyl) -6-azaspiro [2.5] octane-5-carboxamido) -cyclopropyl) benzoic acid or a salt thereof | 罗达制药生物技术有限责任公司 | 2022-12-23 | — | — | CN | disclosed |
| EP-3953393-B1 | PHARMACEUTICAL COMBINATION OF AN EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITORS FOR THE TREATMENT OF TUMOURS | Rottapharm Biotech Srl (IT) | 2022-12-14 | — | — | EP | disclosed |
| US-20220142996-A1 | PHARMACEUTICAL COMBINATION OF AN EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITORS FOR THE TREATMENT OF TUMOURS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2022-05-12 | — | — | US | disclosed |
| EP-3827828-A1 | (R)-4-(1-(6-(4-(TRIFLUOROMETHYL)BENZYL)-6-AZASPIRO[2.5]OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL) BENZOIC ACID OR ITS SALT ALSO IN POLYMORPHIC FORM A FOR USE IN THE PREVENTION OF HETEROTOPIC OSSIFICATION | Rottapharm Biotech S.r.l. (IT) | 2021-06-02 | — | — | EP | disclosed |
| EP-3722319-A1 | PHARMACEUTICAL COMBINATION OF AN EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITORS FOR THE TREATMENT OF TUMOURS | Rottapharm Biotech S.r.l. (IT) | 2020-10-14 | — | — | EP | disclosed |
| US-9181279-B2 | Cyclic amine derivatives as EP4 receptor antagonists | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-11-10 | — | — | US | disclosed |
| US-9181279-B2 | Cyclic amine derivatives as EP4 receptor antagonists | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-11-10 | — | — | US | disclosed |
| US-9181279-B2 | Cyclic amine derivatives as EP4 receptor antagonists | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-11-10 | — | — | US | disclosed |
| EP-2729445-B1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Rottapharm Biotech Srl (IT) | 2015-10-21 | — | — | EP | disclosed |
| US-20150087626-A1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-03-26 | — | — | US | disclosed |
| US-20150087626-A1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-03-26 | — | — | US | disclosed |
| US-20150087626-A1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-03-26 | — | — | US | disclosed |
| EP-2729445-A1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Rottapharm S.p.A. (IT) | 2014-05-14 | — | — | EP | disclosed |
| WO-2013004290-A1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM S.P.A. (IT) | 2013-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142996-A1 | PHARMACEUTICAL COMBINATION OF AN EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITORS FOR THE TREATMENT OF TUMOURS | PTGER4, EPB41, PTGER1 | NR1H2 2814/4885NR1H3 2471/4885PEPD 2691/4885 |
| US-20230028519-A1 | (R)-4-(1-(6-(4-(TRIFLUOROMETHYL)BENZYL)-6-AZASPIRO[2.5] OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL) BENZOIC ACID OR ITS SALT ALSO IN POLYMORPHIC FORM A FOR USE IN THE PREVENTION OF HETEROTOPIC OSSIFICATION | SOST, BMP6, BMP1 | NR1H2 1150/4885NR1H3 1040/4885PEPD 2272/4885 |
| US-12544365-B2 | Pharmaceutical combination of an EP4 antagonist and immune checkpoint inhibitors for the treatment of tumours | PTGER4, CD274, EPB41 | NR1H2 2632/4885NR1H3 2421/4885PEPD 3897/4885 |
| US-11590114-B2 | Pharmaceutical combination of an EP4 antagonist and immune checkpoint inhibitors for the treatment of tumours | PTGER4, EPB41, PTGER1 | NR1H2 2814/4885NR1H3 2471/4885PEPD 2691/4885 |
| US-20150087626-A1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | PTGER4, PTGER1, PTGER3 | NR1H2 445/4885NR1H3 503/4885PEPD 1825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.